Irene Oglesby

Dr. Irene Oglesby

Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
IOIrene Oglesby
Irene Oglesby
IBIsabella M. Bray
Isabella M. Bray
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
RSRaymond L. Stallings
Raymond L. Stallings
SOShane J. O’neill
Shane J. O’neill
Catherine GreeneCatherine Greene
Catherine Greene
Cystic fibrosis (CF) is one of the most common lethal genetic diseases in which the role of microRNAs has yet to be explored. Predicted to be regulated by miR-126, TOM1 (target of Myb1) has been shown to interact with Toll-interacting protein, forming a complex to regulate endosomal trafficking of ubiquitinated proteins. TOM1 has also been proposed as a negative regulator of IL-1β and TNF-α–induced signaling pathways. MiR-126 is highly expressed in the lung, and we now show for the first time differential expression of miR-126 in CF versus non-CF airway epithelial cells both in vitro and in vivo. MiR-126 downregulation in CF bronchial epithelial cells correlated with a significant upregulation of TOM1 mRNA, both in vitro and in vivo when compared with their non-CF counterparts. Introduction of synthetic pre–miR-126 inhibited luciferase activity in a reporter system containing the full length 3′-untranslated region of TOM1 and resulted in decreased TOM1 protein production in CF bronchial epithelial cells. Following stimulation with LPS or IL-1β, overexpression of TOM1 was found to downregulate NF-κB luciferase activity. Conversely, TOM1 knockdown resulted in a significant increase in NF-κB regulated IL-8 secretion. These data show that miR-126 is differentially regulated in CF versus non-CF airway epithelial cells and that TOM1 is a miR-126 target that may have an important role in regulating innate immune responses in the CF lung. To our knowledge, this study is the first to report of a role for TOM1 in the TLR2/4 signaling pathways and the first to describe microRNA involvement in CF.

28 October 2010 in Respiratory Research
Verified
Journal Article
Open access
PDF file
IOIrene Oglesby
Irene Oglesby
NMNoel G McElvaney
Noel G McElvaney
Catherine GreeneCatherine Greene
Catherine Greene
MicroRNAs (miRNAs) have emerged as a class of regulatory RNAs with immense significance in numerous biological processes. When aberrantly expressed miRNAs have been shown to play a role in the pathogenesis of several disease states. Extensive research has explored miRNA involvement in the development and fate of immune cells and in both the innate and adaptive immune responses whereby strong evidence links miRNA expression to signalling pathways and receptors with critical roles in the inflammatory response such as NF-κB and the toll-like receptors, respectively. Recent studies have revealed that unique miRNA expression profiles exist in inflammatory lung diseases such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis and lung cancer. Evaluation of the global expression of miRNAs provides a unique opportunity to identify important target gene sets regulating susceptibility and response to infection and treatment, and control of inflammation in chronic airway disorders. Over 800 human miRNAs have been discovered to date, however the biological function of the majority remains to be uncovered. Understanding the role that miRNAs play in the modulation of gene expression leading to sustained chronic pulmonary inflammation is important for the development of new therapies which focus on prevention of disease progression rather than symptom relief. Here we discuss the current understanding of miRNA involvement in innate immunity, specifically in LPS/TLR4 signalling and in the progression of the chronic inflammatory lung diseases cystic fibrosis, COPD and asthma. miRNA in lung cancer and IPF are also reviewed.

1 April 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
IOIrene Oglesby
Irene Oglesby
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
NMNoel G. McElvaney
Noel G. McElvaney
Catherine GreeneCatherine Greene
Catherine Greene
Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) is altered in individuals with the ΔF508 CFTR mutation. We previously reported differential expression of microRNA (miRNA) in CF airway epithelium; however, the role of miRNA in regulation of CFTR expression here remains unexplored. In this study, we investigated the role of upregulated miRNAs in CFTR regulation in vivo in bronchial brushings from individuals homozygous or heterozygous for ΔF508 CFTR, validated our observations in vitro, and assessed the impact of defective chloride ion conductance, genotype, and colonization status on miRNA expression. miRNA target prediction was performed in silico, and expression of miRNA and target genes were measured by quantitative real-time PCR and/or Western blotting. Overexpression and inhibition studies were performed with pre-miRs or antimiRs, respectively, and a luciferase reporter gene was used to elucidate direct miRNA–target interactions. miR-145, miR-223, and miR-494 were upregulated in CF versus non-CF bronchial brushings and cell lines; in ΔF508 CFTR homozygotes versus heterozygotes; in subjects positive for P. aeruginosa; and in cells treated with a CFTR inhibitor or IL-1β. Reciprocal downregulation or upregulation of CFTR gene and/or protein expression was observed after miRNA manipulation and direct miRNA–target relationships demonstrated via a reporter system containing a wild type or mutated full-length CFTR 3′ untranslated region. Increased expression of miR-145, miR-223, and miR-494 in vivo in bronchial epithelium of individuals carrying the ΔF508 CFTR mutation correlates with decreased CFTR expression. Defective CFTR function, Pseudomonas colonization, and inflammation may affect miRNA expression and contribute to the regulation of ΔF508 CFTR.

1 July 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SCSanjay Haresh Chotirmall
Sanjay Haresh Chotirmall
Catherine GreeneCatherine Greene
Catherine Greene
IOIrene Oglesby
Irene Oglesby
WTWarren Thomas
Warren Thomas
SOShane J. O'NEill
Shane J. O'NEill
NMNoel G. McElvaney
Noel G. McElvaney
Rationale: An unexplained gender gap is observed in cystic fibrosis (CF). Females have poorer lung function, decreased survival, and earlier Pseudomonas colonization. Objectives: To evaluate the effect of 17β-estradiol (E2) on CF bronchial epithelial cells in vitro and in vivo. Methods: On exposure of CFBE41o- cultures to physiological concentrations of E2, there was a significant dose-dependent inhibition of IL-8 release induced by toll-like receptor agonists, CF bronchoalveolar lavage fluid, or Pseudomonas-conditioned media. Estrogen receptor (ER)-α and -β expression was quantified in cell lines and bronchial brushings from CF and non-CF patients. Measurements and Main Results: Both receptors were expressed in vitro and in vivo, although ERβ expression was significantly higher in CF. Using ER isoform-specific agonists and antagonists, we established that ERβ mediates the inhibition of CF bronchoalveolar lavage fluid–induced IL-8 release. We also showed that secretory leucoprotease inhibitor gene expression and protein localization to the nucleus increased in response to E2. Secretory leucoprotease inhibitor knockdown abrogated the inhibitory effects of E2. Conclusions: E2 inhibits IL-8 release by ERβ in CF bronchial epithelial cells through up-regulation of secretory leucoprotease inhibitor, inhibition of nuclear factor (NF)-κB, and IL-8 gene expression. These data implicate a novel anti-inflammatory mechanism for E2 in females with CF, which predisposes to infection and colonization. This could, in part, account for the observed gender dichotomy in CF.

1 July 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Sinead WeldonSinead Weldon
Sinead Weldon
PMPaul McNally
Paul McNally
DMDanny F. McAuley
Danny F. McAuley
IOIrene Oglesby
Irene Oglesby
CWChristine L. Wohlford-Lenane
Christine L. Wohlford-Lenane
Clifford C. TaggartClifford C. Taggart
Clifford C. Taggart
Rationale: Cathepsin S (CTSS) activity is increased in bronchoalveolar lavage (BAL) fluid from patients with cystic fibrosis (CF). This activity contributes to lung inflammation via degradation of antimicrobial proteins, such as lactoferrin and members of the β-defensin family. Objectives: In this study, we investigated the hypothesis that airway epithelial cells are a source of CTSS, and mechanisms underlying CTSS expression in the CF lung. Methods: Protease activity was determined using fluorogenic activity assays. Protein and mRNA expression were analyzed by ELISA, Western blotting, and reverse-transcriptase polymerase chain reaction. Measurements and Main Results: In contrast to neutrophil elastase, CTSS activity was detectable in 100% of CF BAL fluid samples from patients without Pseudomonas aeruginosa infection. In this study, we identified epithelial cells as a source of pulmonary CTSS activity with the demonstration that CF airway epithelial cells express and secrete significantly more CTSS than non-CF control cells in the absence of proinflammatory stimulation. Furthermore, levels of the transcription factor IRF-1 correlated with increased levels of its target gene CTSS. We discovered that miR-31, which is decreased in the CF airways, regulates IRF-1 in CF epithelial cells. Treating CF bronchial epithelial cells with a miR-31 mimic decreased IRF-1 protein levels with concomitant knockdown of CTSS expression and secretion. Conclusions: The miR-31/IRF-1/CTSS pathway may play a functional role in the pathogenesis of CF lung disease and may open up new avenues for exploration in the search for an effective therapeutic target.

9 July 2015 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
IOIrene Oglesby
Irene Oglesby
SVSebastian F. Vencken
Sebastian F. Vencken
RARaman Agrawal
Raman Agrawal
KGKevin Gaughan
Kevin Gaughan
KMKevin Molloy
Kevin Molloy
Catherine GreeneCatherine Greene
Catherine Greene
Interleukin (IL)-8 levels are higher than normal in cystic fibrosis (CF) airways, causing neutrophil infiltration and non-resolving inflammation. Overexpression of microRNAs that target IL-8 expression in airway epithelial cells may represent a therapeutic strategy for cystic fibrosis.IL-8 protein and mRNA were measured in cystic fibrosis and non-cystic fibrosis bronchoalveolar lavage fluid and bronchial brushings (n=20 per group). miRNAs decreased in the cystic fibrosis lung and predicted to target IL-8 mRNA were quantified in βENaC-transgenic, cystic fibrosis transmembrane conductance regulator (Cftr)-/-and wild-type mice, primary cystic fibrosis and non-cystic fibrosis bronchial epithelial cells and a range of cystic fibrosisversusnon-cystic fibrosis airway epithelial cell lines or cells stimulated with lipopolysaccharide,Pseudomonas-conditioned medium or cystic fibrosis bronchoalveolar lavage fluid. The effect of miRNA overexpression on IL-8 protein production was measured.miR-17 regulates IL-8 and its expression was decreased in adult cystic fibrosis bronchial brushings, βENaC-transgenic mice and bronchial epithelial cells chronically stimulated withPseudomonas-conditioned medium. Overexpression of miR-17 inhibited basal and agonist-induced IL-8 protein production in F508del-CFTR homozygous CFTE29o−tracheal, CFBE41o−and/or IB3 bronchial epithelial cells.These results implicate defective CFTR, inflammation, neutrophilia and mucus overproduction in regulation of miR-17. Modulating miR-17 expression in cystic fibrosis bronchial epithelial cells may be a novel anti-inflammatory strategy for cystic fibrosis and other chronic inflammatory airway diseases.